Meeting
2021 ASCO Annual Meeting
Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.
Authors
Masayuki Shirasawa
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Masayuki Shirasawa , Tatsuya Yoshida , Yukiko Shimoda , Daisuke Takayanagi , Kouya Shiraishi , Takashi Kubo , Sachiyo Mitani , Yuji Matsumoto , Ken Masuda , Yuki Shinno , Yusuke Okuma , Yasushi Goto , Hidehito Horinouchi , Hitoshi Ichikawa , Takashi Kohno , Noboru Yamamoto , Shun-ichi Watanabe , Noriko Motoi , Yuichiro Ohe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9044)
DOI
10.1200/JCO.2021.39.15_suppl.9044
Abstract #
9044
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
First Author: Kiyotaka Yoh
Poster
2019 ASCO Annual Meeting
Mutational landscapes and PD-L1 expression in non-small cell lung cancer.
First Author: Kang Zhang
Poster
2023 ASCO Annual Meeting
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.
First Author: Mo Yang
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates